` CEL (Celadon Pharmaceuticals PLC) vs FTSE All Share Index Comparison - Alpha Spread

C
CEL
vs
F
FTSE All Share Index

Over the past 12 months, CEL has outperformed FTSE All Share Index, delivering a return of -34% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
CEL vs FTSE All Share Index

Loading
CEL
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CEL vs FTSE All Share Index

Loading
CEL
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
CEL vs FTSE All Share Index

Loading
CEL
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Celadon Pharmaceuticals PLC vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Celadon Pharmaceuticals PLC
Glance View

Market Cap
9.2m GBX
Industry
N/A

Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.

CEL Intrinsic Value
22.51 GBX
Undervaluation 40%
Intrinsic Value
Price
C
Back to Top